PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer
Loss of Appetite
Colorectal Cancer
Cachexia
Pancreatic Cancer
Fatigue

Interventions: Drug: ponsegromab
Drug: Placebo for ponsegromab

First Posted Date: 2022-09-19

Last Posted Date: 2025-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 187

Registration Number: NCT05546476

Locations: 🇧🇬
University Multiprofile Hospital for Active Treatment Sofiamed, Sofia, Bulgaria
🇧🇬
Complex Oncology Center - Vratsa, Vratsa, Bulgaria
🇨🇦
The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada

and more 75 locations

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

Phase 2

Withdrawn

Conditions: Coronavirus Disease 2019 (COVID-19)
Hospitalization
Child, Hospitalized
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Immunocompromised

Interventions: Drug: Nirmatrelvir
Drug: Placebo for nirmatrelvir
Drug: Ritonavir

First Posted Date: 2022-09-19

Last Posted Date: 2023-03-01

Lead Sponsor: Pfizer

Registration Number: NCT05545319

Locations: 🇧🇬
Multiprofile Hospital for Active Treatment - Sveti Nikolay Chudotvoretz, Lom, Montana, Bulgaria
🇧🇬
Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases - Haskovo EOOD, Haskovo, Bulgaria
🇧🇬
"University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski" EAD, Pleven, Bulgaria

and more 8 locations

Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

Phase 1

Completed

Conditions: Biological Availability

Interventions: Drug: Nirmatrelvir/ritonavir
Drug: Nirmatrelvir/ ritonavir

First Posted Date: 2022-09-16

Last Posted Date: 2024-05-10

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05544786

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Biological: Quadrivalent influenza vaccine
Biological: Quadrivalent influenza modRNA vaccine

First Posted Date: 2022-09-14

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 45789

Registration Number: NCT05540522

Locations: 🇳🇿
P3 Research - Wellington, Wellington, New Zealand
🇵🇭
De La Salle Health Sciences Institute, Dasmarinas City, Philippines
🇵🇭
De La Salle Medical and Health Sciences Institute, Dasmarinas, Philippines

and more 296 locations

A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Melanoma
Glioma
Thyroid Cancer
Non-Small Cell Lung Cancer
Malignant Neoplasms
Brain Neoplasms
Colorectal Cancer

Interventions: Drug: PF-07799544
Drug: encorafenib
Drug: PF-07799933

First Posted Date: 2022-09-13

Last Posted Date: 2025-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 124

Registration Number: NCT05538130

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center 53rd street., New York, New York, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Columbia University Medical Center - Neurological Institute of New York, New York, New York, United States

and more 36 locations

A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: vepdegestrant
Drug: Itraconazole

First Posted Date: 2022-09-13

Last Posted Date: 2023-06-23

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05538312

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

Terminated

Conditions: Carcinoma, Renal Cell

First Posted Date: 2022-09-10

Last Posted Date: 2025-01-20

Lead Sponsor: Pfizer

Target Recruit Count: 106

Registration Number: NCT05534789

Locations: 🇺🇸
Pfizer New York, New York, New York, United States

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07261271
Drug: Placebo

First Posted Date: 2022-09-10

Last Posted Date: 2025-03-24

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT05536440

Locations: 🇺🇸
Clinilabs, Eatontown, New Jersey, United States
🇺🇸
ICON, Salt Lake City, Utah, United States
🇺🇸
Orange County Research Center, Tustin, California, United States

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants
Biological Availability

Interventions: Drug: Nirmatrelvir/ritonavir
Drug: Nirmatrelvir/ ritonavir

First Posted Date: 2022-09-02

Last Posted Date: 2022-12-16

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT05525910

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

Conditions: Alopecia Areata

First Posted Date: 2022-08-31

Last Posted Date: 2024-11-15

Lead Sponsor: Pfizer

Registration Number: NCT05522556

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy